Cervical Squamous Cell Carcinoma of Unknown Primary: Oncological Outcomes and Prognostic Factors

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 1

PMID 36452507

Authors

Jeroen Meulemans

Jens Voortmans

Sandra Nuyts

Jean-Francois Daisne

Paul Clement

Annouschka Laenen

Pierre Delaere

Charlotte van Lierde

Vincent Vander Poorten

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Cervical squamous cell carcinoma of unknown primary (SCCUP) is a rare entity within head and neck cancer and both treatment regimens as well as identified potential predictors for oncological outcomes vary between published series. In this study, we evaluated oncological outcomes and identified potential prognostic factors for outcome.

Patients And Methods: This retrospective monocentric cohort study includes 82 SCCUP patients diagnosed and treated between January 2000 and June 2021. Overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and locoregional recurrence-free survival (LRFS) were evaluated. The Cox proportional hazards model was used to analyze the prognostic effect of patient and tumor characteristics on oncological outcomes.

Results: Five year OS, DSS, DFS and LRFS were respectively 53.9%, 72.2%, 68.9% and 67.3%. The p16 status was evaluated in 55 patients with 40% being p16 positive. On univariable analysis, p16 negative SCCUPs had significantly worse survival and recurrence rates in the presence of clinical extranodal extension (cENE) (OS: p=0.0013, DSS: p=0.0099, DFS: p=0.0164, LRFS: p=0.0099) and radiological extranodal extension (rENE) (OS: p=0.0034, DSS: p=0.0137, DFS: p=0.0167, LRFS: p=0.0100). In p16 positive SCCUP patients, rENE had a significantly negative prognostic effect on DFS (p=0.0345) and LRFS (p=0.0367). Total group multivariate analysis identified rENE as an independent negative predictor for all oncological outcomes. The "number of positive lymph nodes" was a second independent predictor for DSS (p=0.0257) and DFS (p=0.0435).

Conclusions: We report favorable oncological outcomes, comparable to previously published results. Although the presence of rENE seems associated with poor oncological outcomes, the differential effect of clinical, radiological and pathological ENE in both p16 positive and negative subgroups remain to be elucidated by further prospective research.

References

Cosway B, Drinnan M, Paleri V . Narrow band imaging for the diagnosis of head and neck squamous cell carcinoma: A systematic review. Head Neck. 2016; 38 Suppl 1:E2358-67. DOI: 10.1002/hed.24300. View

Pilar A, Yu E, Su J, OSullivan B, Bartlett E, Waldron J . Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. Oral Oncol. 2021; 114:105167. DOI: 10.1016/j.oraloncology.2020.105167. View

Rassy E, Boussios S, Pavlidis N . Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. Eur J Clin Invest. 2021; 51(9):e13583. DOI: 10.1111/eci.13583. View

Lydiatt W, Patel S, OSullivan B, Brandwein M, Ridge J, Migliacci J . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-137. DOI: 10.3322/caac.21389. View

Lee M, Fowler N, Adelstein D, Koyfman S, Prendes B, Burkey B . Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin. Anticancer Res. 2020; 40(8):4207-4214. DOI: 10.21873/anticanres.14421. View

Schroeder L, Boscolo-Rizzo P, Cin E, Romeo S, Baboci L, Dyckhoff G . Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. Eur J Cancer. 2017; 74:73-81. DOI: 10.1016/j.ejca.2016.12.020. View

Lewis Jr J, Beadle B, Bishop J, Chernock R, Colasacco C, Lacchetti C . Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2017; 142(5):559-597. DOI: 10.5858/arpa.2017-0286-CP. View

Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Saito T, Kawamori J . Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2019; 276(4):1221-1229. DOI: 10.1007/s00405-019-05338-3. View

Dunne A, Muller H, Eisele D, Kessel K, Moll R, Werner J . Meta-analysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients. Eur J Cancer. 2006; 42(12):1863-8. DOI: 10.1016/j.ejca.2006.01.062. View

10.

Kamal M, Mohamed A, Fuller C, Sturgis E, Johnson F, Morrison W . Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018; 124(7):1415-1427. PMC: 11362832. DOI: 10.1002/cncr.31235. View

11.

Cheraghlou S, Torabi S, Husain Z, Otremba M, Osborn H, Mehra S . HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. Laryngoscope. 2018; 129(3):684-691. DOI: 10.1002/lary.27475. View

12.

Zhou M, van Zante A, Lazar A, Groppo E, Garsa A, Ryan W . Squamous cell carcinoma of unknown primary of the head and neck: Favorable prognostic factors comparable to those in oropharyngeal cancer. Head Neck. 2017; 40(5):904-916. DOI: 10.1002/hed.25028. View

13.

Hung Y, Liu S, Wang C, Wang C, Jiang R, Wu S . Treatment outcomes of unknown primary squamous cell carcinoma of the head and neck. PLoS One. 2018; 13(10):e0205365. PMC: 6193660. DOI: 10.1371/journal.pone.0205365. View

14.

Axelsson L, Holmberg E, Nyman J, Hogmo A, Sjodin H, Gebre-Medhin M . Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival. Int Arch Otorhinolaryngol. 2021; 25(3):e433-e442. PMC: 8321641. DOI: 10.1055/s-0040-1712106. View

15.

Rassy E, Labaki C, Chebel R, Boussios S, Smith-Gagen J, Greco F . Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treat Rev. 2022; 107:102407. DOI: 10.1016/j.ctrv.2022.102407. View

16.

Mermod M, Tolstonog G, Simon C, Monnier Y . Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2016; 62:60-71. DOI: 10.1016/j.oraloncology.2016.10.003. View

17.

Civantos F, Vermorken J, Shah J, Rinaldo A, Suarez C, Kowalski L . Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. Front Oncol. 2020; 10:593164. PMC: 7685177. DOI: 10.3389/fonc.2020.593164. View

18.

Sivars L, Nasman A, Tertipis N, Vlastos A, Ramqvist T, Dalianis T . Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med. 2014; 3(2):376-84. PMC: 3987086. DOI: 10.1002/cam4.199. View

19.

Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A . Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019; 88:145-152. DOI: 10.1016/j.oraloncology.2018.11.020. View

20.

Meccariello G, Cammaroto G, Ofo E, Calpona S, Parisi E, DAgostino G . The emerging role of trans-oral robotic surgery for the detection of the primary tumour site in patients with head-neck unknown primary cancers: A meta-analysis. Auris Nasus Larynx. 2019; 46(5):663-671. DOI: 10.1016/j.anl.2019.04.007. View